Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.

Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.

Bibliographic Details
Main Authors: Elda eTagliabue, Manuela eCampiglio
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-11-01
Series:Frontiers in Oncology
Subjects:
omics
breast cancer
targeted therapy
HER2
Trastuzumab resistance
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/full
id doaj-461242d86c0c446297ab910c223fdce7
record_format Article
spelling doaj-461242d86c0c446297ab910c223fdce72020-11-24T22:54:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-11-01410.3389/fonc.2014.00334122788Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.Elda eTagliabue0Manuela eCampiglio1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan ItalyFondazione IRCCS Istituto Nazionale dei Tumori, Milan Italyhttp://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/fullomicsbreast cancertargeted therapyHER2Trastuzumab resistance
collection DOAJ
language English
format Article
sources DOAJ
author Elda eTagliabue
Manuela eCampiglio
spellingShingle Elda eTagliabue
Manuela eCampiglio
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
Frontiers in Oncology
omics
breast cancer
targeted therapy
HER2
Trastuzumab resistance
author_facet Elda eTagliabue
Manuela eCampiglio
author_sort Elda eTagliabue
title Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
title_short Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
title_full Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
title_fullStr Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
title_full_unstemmed Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
title_sort omics and immunologic approaches to optimizing cure rates in her2-positive breast carcinomas.
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2014-11-01
topic omics
breast cancer
targeted therapy
HER2
Trastuzumab resistance
url http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/full
work_keys_str_mv AT eldaetagliabue omicsandimmunologicapproachestooptimizingcureratesinher2positivebreastcarcinomas
AT manuelaecampiglio omicsandimmunologicapproachestooptimizingcureratesinher2positivebreastcarcinomas
_version_ 1725661404539650048

Similar Items